Roche’s Q1 2016 Earnings Support Our Bullish Stance

+29.53%
Upside
32.64
Market
42.28
Trefis
RHHBY: Roche logo
RHHBY
Roche

Key Takeaways From Roche’s Q1 2016 Earnings

  • Cancer Behemoths Avastin, Herceptin & Rituxan Are Still Growing
  • New Cancer Drugs Have Significant Growth Potential
  • Drug Pipeline Is Looking Interesting
  • Overall, Earnings Results Re-Affirm Our Bullish Stance On Roche

Roche_Q19_1

Roche_Q19_2

Relevant Articles
  1. Is Roche Stock Undervalued At $33?
  2. What’s Driving Roche Stock?
  3. Company Of The Day: Roche Holdings
  4. What’s Happening With Roche (RHHBY) Stock?
  5. What’s Next For Roche Stock?
  6. Should You Buy, Sell, Or Hold Roche Stock At $42?

Have more questions about Roche? See the links below.

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Roche

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology